HMDCF
HUTCHMED (China) Ltd
$2.16
0.00%
No data for this timeframe.
Vol
SEC Reports5
Recent Activity
May 21, 2026
SEC
HUTCHMED and Innovent announced NMPA approval for ELUNATE (fruquintinib) in combination with TYVYT (sintilimab) for seco
6-K — Impact 7/10
May 12, 2026
SEC
HUTCHMED reported that all resolutions at its May 12, 2026 Annual General Meeting were passed, including re-election of
6-K — Impact 1/10
Apr 29, 2026
SEC
HUTCHMED announced that its NDA for sovleplenib in warm antibody autoimmune hemolytic anemia (wAIHA) was accepted for re
6-K — Impact 7/10
Analyst Ratings
10Strong Buy
13Buy
3Hold
0Sell
0Strong Sell
Latest Reports
BULLISH
6-K
7/10
HUTCHMED and Innovent announced NMPA approval for ELUNATE (fruquintinib) in combination with TYVYT (sintilimab) for seco
May 21, 2026
NEUTRAL
6-K
1/10
HUTCHMED reported that all resolutions at its May 12, 2026 Annual General Meeting were passed, including re-election of
May 12, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
5 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 4.4/10.
BULLISH
6-K
7/10
HUTCHMED and Innovent announced NMPA approval for ELUNATE (fruquintinib) in combination with TYVYT (
May 21, 2026
NEUTRAL
6-K
1/10
HUTCHMED reported that all resolutions at its May 12, 2026 Annual General Meeting were passed, inclu
May 12, 2026
BULLISH
6-K
7/10
HUTCHMED announced that its NDA for sovleplenib in warm antibody autoimmune hemolytic anemia (wAIHA)
Apr 29, 2026
NEUTRAL
6-K
5/10
HUTCHMED announced upcoming presentations of preclinical data for its novel ATTC candidate HMPL-A580
Apr 9, 2026
NEUTRAL
6-K
2/10
HUTCHMED (China) Ltd is holding its annual general meeting to re-elect directors, renew mandates for
Apr 9, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 88% buy across 26 analysts — 10 strong buy, 13 buy, 3 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.6B | 17.0% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.7B | 14.6% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 10 | 13 | 3 | 0 | 0 | 88% | |
| May 1, 2026 | 10 | 14 | 2 | 1 | 0 | 89% | |
| Apr 1, 2026 | 10 | 14 | 2 | 1 | 0 | 89% | |
| Mar 1, 2026 | 9 | 12 | 2 | 1 | 0 | 88% | |
| Feb 1, 2026 | 9 | 12 | 2 | 1 | 0 | 88% | |
| Jan 1, 2026 | 9 | 15 | 2 | 1 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 4, 2026
Clinical Trial
Phase III Study on HMPL-523 for Treatment of ITP
Phase Phase 3 — COMPLETED